Labcorp (LH) recently reported strong Q4 2025 results, with higher sales and earnings, and issued positive 2026 revenue guidance. The company also launched an FDA-cleared Alzheimer’s blood test, Elecsys pTau-181, which is expected to support its push into higher-value diagnostics. These developments, along with its share repurchase program, could significantly impact its long-term investment narrative and growth potential, though competitive pressures and reimbursement risks remain.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Alzheimer’s Test Launch And 2026 Outlook Might Change The Case For Investing In Labcorp (LH)
Labcorp (LH) recently reported strong Q4 2025 results, with higher sales and earnings, and issued positive 2026 revenue guidance. The company also launched an FDA-cleared Alzheimer’s blood test, Elecsys pTau-181, which is expected to support its push into higher-value diagnostics. These developments, along with its share repurchase program, could significantly impact its long-term investment narrative and growth potential, though competitive pressures and reimbursement risks remain.